Subscribe to our mailing list to receive up-to-date information.
TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH
Neglected infectious diseases
The aim is to establish an integrated approach for the development of preventive, therapeutic and diagnostic tools for neglected infectious diseases. Activities in this area will include, but not be limited to, parasitic diseases caused by Trypanosomatidae species (e.g. Trypanosomiasis, Chagas Disease, Leishmaniasis), bacterial diseases such as Buruli ulcer, leprosy and trachoma, helminth diseases such as schistosomiasis, filariasis as well as other neglected infectious diseases such as infantile diarrhoea.
Projects should address preclinical and early clinical activities, as well as the particular health conditions and health needs of disease endemic countries. Proposals involving an integrated multidisciplinary approach, including significant participation of partners from disease-endemic areas and, where relevant, industry partners, will be strongly encouraged. Where applicable, technology transfer, training activities and human capacity building should also be part of the projects.
Expected impact: Research in this area will gather the necessary critical mass in
several fields of expertise to achieve integration of basic science and enabling
technologies with the aim of expediting the discovery and development of vaccine and
new drug candidates. The European added value will be to increase the innovation
potential and competitiveness of translational research. It will enhance the cooperation
between scientific disciplines and stakeholders at European level with disease-endemic
countries on the basis of mutual interest and shared benefits. It will provide sound
scientific substantiation for developing new prophylactics or new drug candidates that
can address the therapeutic gap of existing treatments.
HEALTH-2009-4.3.1-1: Discovery and development of new vaccines or drugs for helminth infections. FP7-HEALTH-2009-single-stage.
State-of-the-art technologies, including bioinformatics and applied genomics, where available should be used to identify and develop candidates for either prophylactic vaccines or for new treatments for helminth infections such as schistosomiasis and lymphatic filariasis. Projects may also focus on identification of new lead compounds or improvement of existing compounds to overcome drug resistance. Pre-clinical testing in vitro and in vivo should be an intrinsic part of the project, which may also include early clinical testing. Inclusion of participants from disease-endemic countries is expected. Active participation of industry, especially SMEs, could lead to an increased impact of the research proposed, and this will be considered in the evaluation of the proposal.
Target Regions: All International
Cooperation Partner Countries, see annex I of the work programme.
HEALTH-2009-4.3.1-2: Identification and development of vaccine candidates for neglected bacterial infections. FP7-HEALTH-2009-single-stage.
Projects should aim to identify and develop new vaccine candidates for neglected bacterial, including mycobacterial infections, with priority given to pathogens causing trachoma, leprosy and/or Buruli ulcer. Essential pre-clinical testing in vitro and in vivo should be an intrinsic part of the project, which may also address correlates of protection, disease immunopathology, and advancement of existing vaccine lead candidates to phase I clinical trials. Recent scientific advances in bioinformatics and applied genomics should be used whenever relevant. Active participation of industry, especially SMEs, could lead to an increased impact of the research proposed, and this will be considered in the evaluation of the proposal.
Regions: All International Cooperation Partner Countries, see annex I of the work
HEALTH-2009-4.3.1-3: Human immune responses to co-infections of poverty-related (HIV, malaria, TB) and neglected infectious diseases. FP7- HEALTH-2009-single-stage.
Lack of a thorough understanding of the human immune responses to co-infections by virus, unicellular eukaryotic parasites, bacteria or worm infections as well as the influence of such co-infections on the pathogenesis of the involved diseases are causing a severe disease burden in Developing Countries. This is hampering the efficient use of antimicrobial agents as well as the development of potent prophylactic vaccines. Projects need to address the identification of immune surrogates of protection and, the elucidation of the role of the innate immune system in triggering an efficient immune response in individuals affected by two or more infectious diseases. Sustainable networking with research partners in disease-endemic countries should be an essential part of the project, which should provide an integrated immunological research effort across disciplines and diseases. Child health and ageing aspects should be taken into consideration wherever appropriate.
Target Regions: ACP Countries see
annex I of the work programme.